Fletcher, who joined RMS Medical as an independent board member in May 2019, has more than 35 years of healthcare and medical device experience. He joined the Board of Directors of publicly traded medical device company Spectranetics Corporation in 2002 and served as the company’s chairman from 2010-2017. Spectranetics was acquired by Royal Philips in 2017 for $2.2 billion, representing a seven-fold increase in share price during his tenure as chairman. Fletcher was named 2018 Director of the Year by The National Association of Corporate Directors (NACD) for his work at Spectranetics. He currently serves as CEO and managing director of Fletcher Spaght Inc., a strategy consulting and venture capital firm, which he founded in 1983.
“We are thrilled to announce John’s elevation to chairman of RMS Medical,” said Don Pettigrew, president and CEO. “As a member of our board, we have benefited from John’s vision, perspective, deep industry experience, and informed counsel. We will continue to draw on John’s leadership to help RMS Medical grow and evolve as a preferred provider of home and specialty infusion products.”
“I am honored to take on this new role,” said Fletcher. “These are exciting times for both RMS Medical and the home infusion industry. I look forward to working with my board colleagues and the management team to achieve our long-term objectives to maximize value for shareholders.”
Pettigrew concluded, “We would like to thank Dan for all he has contributed to RMS Medical’s growth and look forward to his continuing support as a member of the board.”
RMS Medical develops, manufactures, and commercializes specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, RMS Precision Flow Rate Tubing and RMS HIgH-Flo Subcutaneous Safety Needle Sets. These devices are used for infusions administered in the home and alternate care settings.